Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity

Kenneth A. Freedberg; Robert B. Innis; Ian Creese; Solomon H. Snyder

doi:10.1016/0024-3205(79)90457-0

Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity

Kenneth A. Freedberg, Robert B. Innis, Ian Creese, Solomon H. Snyder

School of Medicine

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

Original language	English (US)
Pages (from-to)	2467-2473
Number of pages	7
Journal	Life Sciences
Volume	24
Issue number	26
DOIs	https://doi.org/10.1016/0024-3205(79)90457-0
State	Published - Jun 25 1979

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/0024-3205(79)90457-0

Cite this

@article{0d6d39b10f7b4ab08f592a313d4bfa92,

title = "Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity",

abstract = "The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.",

author = "Freedberg, {Kenneth A.} and Innis, {Robert B.} and Ian Creese and Snyder, {Solomon H.}",

note = "Funding Information: Robert B . lams is the recipient of a fellowship from the Insurance Medical Scientist Training Fund sponsored by the Mutual of Omaha Insurance Co .",

year = "1979",

month = jun,

day = "25",

doi = "10.1016/0024-3205(79)90457-0",

language = "English (US)",

volume = "24",

pages = "2467--2473",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "26",

}

TY - JOUR

T1 - Antischizophrenic drugs

T2 - Differential plasma protein binding and therapeutic activity

AU - Freedberg, Kenneth A.

AU - Innis, Robert B.

AU - Creese, Ian

AU - Snyder, Solomon H.

N1 - Funding Information: Robert B . lams is the recipient of a fellowship from the Insurance Medical Scientist Training Fund sponsored by the Mutual of Omaha Insurance Co .

PY - 1979/6/25

Y1 - 1979/6/25

N2 - The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

AB - The percentage of free neuroleptic drug unbound to plasma protein is much higher for the respective metabolites of chlorpromazine and thioridazine, 7-hydroxychlorpromazine and mesoridazine, than for the parent drugs. The therapeutic activities of chlorpromazine and thioridazine may be mediated to a major extent by 7-hydroxychlorpromazine and mesoridazine respectively. Measuring free levels of the active metabolites of neuroleptics as well as the parent drugs may facilitate regulation of neuroleptic doses to secure optimal therapeutic responses.

UR - http://www.scopus.com/inward/record.url?scp=0018743954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018743954&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(79)90457-0

DO - 10.1016/0024-3205(79)90457-0

M3 - Article

C2 - 39211

AN - SCOPUS:0018743954

SN - 0024-3205

VL - 24

SP - 2467

EP - 2473

JO - Life Sciences

JF - Life Sciences

IS - 26

ER -

Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this